SCHEMBL4417183

SCHEMBL4417183

O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N2C[C@H](O)C[C@@H]12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.55
KMT2A Q03164 2/20 0.52
TP53 P04637 1/20 0.52
GLA P06280 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
THRB P10828 1/20 0.52
RIPK1 Q13546 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
LMNA P02545 1/20 0.52
PKM P14618 1/20 0.52
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6454864 1.00 IDO1 (0.55) IDO1KMT2ATP53GLACYP3A4
SCHEMBL29648879 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29648945 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29648946 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24403852 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24403853 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24403855 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24403876 0.94 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29648915 0.87 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29648816 0.86 TACR2 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1495022-B1 DIAZABICYCLO ALKANE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY SOLVAY PHARM BV (NL) 2009-07-08 EP disclosed
US-7202238-B2 Diazabicyclo alkane derivatives with NK1 antagonistic activity SOLVAY PHARMACEUTICALS B.V. (NL) 2007-04-10 US disclosed
US-20050119267-A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity SOLVAY PHARMACEUTICALS B.V. (NL) 2005-06-02 US disclosed
EP-1495022-A1 DIAZABICYCLO ALKANE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY Solvay Pharmaceuticals B.V. (NL) 2005-01-12 EP disclosed
WO-2003084955-A1 DIAZABICYCLO ALKANE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY SOLVAY PHARMACEUTICALS B.V. (NL) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119267-A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity TAC3, TACR2, OPRK1 IDO1 218/4885KMT2A 1236/4885TP53 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.